U.S. markets closed

OKYO Pharma Limited (OKYO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.6700-0.0300 (-1.76%)
At close: 03:53PM EST
1.6700 0.00 (0.00%)
After hours: 05:20PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close1.7000
Bid1.6500 x 1400
Ask1.7200 x 4000
Day's Range1.6600 - 1.7200
52 Week Range0.9200 - 7.0000
Avg. Volume127,607
Market Cap54.594M
Beta (5Y Monthly)-2.83
PE Ratio (TTM)N/A
EPS (TTM)-0.6100
Earnings DateDec 28, 2023 - Jan 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OKYO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OKYO Pharma Limited
    Daily – Vickers Top Insider Picks for 02/08/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • GlobeNewswire

    OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

    Top-line Efficacy and Safety Data on Track for Release in December 2023LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce the last patient of a planned 240-patient double-blind plac

  • GlobeNewswire

    OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

    Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, materially reducing current payables LONDON and NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), a clinical stage biopharmaceutical company developing innovative therapies for

  • GlobeNewswire

    OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

    OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clinical trial to treat dry eye disease, with top-line data anticipated in December 2023. LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical compa